Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.
Subtle differences in speech timing, vocal effort, and voice quality were found between cannabis and control groups. After controlling for lifetime alcohol and tobacco use, the cannabis group presented with longer and more variable pauses across tasks, and vocal effort was different compared to controls. Vocal effort and intensity also appeared to change in line with duration of abstinence from cannabis use – that is, they appeared get better the longer they stayed away from the drug. The differences observed between users and controls may reflect longer term changes to the underlying neural control of speech.
Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical trials statistics program and data analytics development. He brings expertise in mathematical statistics and a background in experimental psychology.
Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).
Redenlab pediatric specialist Prof Angela Morgan co-authors a new study on speech models in minimally verbal children with autism spectrum disorder. The collaboration with scientists from Boston and Melbourne provides preliminary evidence that subphenotypes of children with MV ASD may exist.
Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.
Acoustic features that predict healthy aging are different than those previously reported for the pathologic voice. We propose a model of healthy and pathologic voice development in which voice characteristics are mediated by the inability to monitor vocal productions associated with age-related hearing loss.
Miglustat is currently the only approved disease-specific treatment shown to be effective in stabilizing neurological symptoms. Miglustat has previously been reported to halt or improve early dysphagia and cognitive symptoms. Here we examine the characteristics of dysphagia, the relationship between dysphagia and the presence of cognitive impairment, and longitudinal changes in swallowing function during miglustat treatment in adult-and-adolescent-onset NPC.
FOXP1-related disorder is characterized by a complex speech and language phenotype with prominent dysarthria, broader motor planning and programming deficits, and linguistic-based phonological errors. Diagnosis of the speech phenotype associated with FOXP1-related dysfunction will inform early targeted therapy.
Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?
Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.
Published in the European Journal of Human Geneticswe expand the linguistic phenotype associated with SETBP1 LoF syndrome (SETBP1 haploinsufficiency disorder), revealing a striking speech presentation that implicates both motor (CAS, dysarthria) and language (phonological errors) systems, with CAS (80%) being the most common diagnosis.
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.
Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.
Published in Journal of Autism and Developmental Disordershttps://link.springer.com/article/10.1007%2Fs10803-018-3565-2 This study used a prospective community-based sample to describe patterns and predictors of...
Published in Journal of Pediatricshttps://www.sciencedirect.com/science/article/pii/S0022347618302944ObjectiveTo characterize the organization of speech- and language-related white matter tracts in children with developmental speech...